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The hypothesis that certain amino acid analogues possessing a five-membered ring 
structure or amino acid analogues that can be viewed as fragments derived from 
such a ring would have anticonvulsant activity was proposed and tested. The 
compounds 1-aminocyclopentane carboxylic acid, l-amino-3-methylcyclopentane 
carboxylic acid, 3-aminotetrahydrothiophene carboxylic acid, and c~-aminoiso- 
butyric acid were found to protect rats against seizures in the maximal electro- 
shock test but offered no protection against metrazol- (pentylenetetrazol) induced 
seizures in mice. The structural feature of this class of anticonvulsants that allows 
for hydrophobic interactions at the receptor site is considered to be a major phys- 
ical factor necessary in promoting the activity of this class of anticonvulsants. 
INTRODUCTION 
In previous investigations we have shown that a number of bicyclic amino 
acid analogues can effectively discriminate between the A and L transport 
systems in both eukaryotic and prokaryotic cells (1-3). In addition, we 
found that a number of these amino acid analogues can selectively elevate 
or depress the endogenous amino acid pool in rat brain (4) and that one 
of the bicyclic analogues can function as a competitive inhibitor of several 
branched-chain aminoacylsynthetases (5). Reports by other investigators 
(6,7) have suggested that the endogenous brain amino acid pool has a 
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participatory role in the pathogenesis of epilepsy. It has also been sug- 
gested that transient changes in brain tissue amino acid concentrations 
may occur during seizure activity (8,9). An additional factor supporting 
the involvement of certain amino acids in the epileptic condition is that 
amino acid analysis of focal and surrounding regions of eleptogenic brain 
reveals that the levels of GABA, aspartic acid, glutamic acid, alanine, 
and taurine are often reduced below normal in eleptogenic foci and the 
level of glycine is frequently elevated (10). Not only have the amino acids 
GABA, glutamic acid, and taurine been used as anticonvulsant agents in 
the control of some forms of epilepsy that were induced in laboratory 
animals (11-13), but also taurine has been used as an antiepileptic in 
humans (14). The most widely used anticonvulsant, diphenylhydantoin, 
reportedly decreases the endogenous levels of glutamic acid and increases 
the concentrations of glutamine and GABA in brain (15). 
Structural considerations of anticonvulsant compounds have led to the 
generalization that a large number of these compounds have geometries 
dominated by a five- or six-membered ring in their skeletal structure (16). 
It is also known that the excitatory or inhibitory properties of certain 
linear amino acids are potentiated if the linear structure is replaced by 
a ring structure (16). These various considerations suggested that the 
amino acid analogues that had been synthesized for our previous studies 
(Table I) should be screened for their potential anticonvulsant activity. 
This study reports our findings on the effectiveness of the four amino acid 
analogues depicted in Fig. 1, as anticonvulsant agents in the maximal 
electroshock test in rats and the metrazol test in mice. 
T A B L E I  
1-Aminocyclopentane carboxylic acid 
1-Aminocyclohexane carboxylic acid 
1-Aminocycloheptane carboxylic acid 
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FIG. 1. Structures of the anticonvulsant amino acid analogues and their abbreviated name 
designations. 
EXPERIMENTAL PROCEDURE 
The amino acid analogues were synthesized and purified as described previously (4). The 
compounds l-aminocyclopentane carboxylic acid (ACPC) and c~-aminoisobutyric acid (AIB) 
were dissolved in physiological saline while 3-methyl-l-aminocyclopentane carboxylic acid 
(3-MACPC) and 3-amino-3-carboxyl tetrahydrothiophene (3-ACTHT) were dispersed in 
physiological saline by the addition of 4-6  drops of Tween 80. The test solutions were then 
adjusted to the desired concentration and administered intraperitoneally. Control animals 
received identical volumes of solution of the same osmolarity but lacking the amino acid 
analogue. 
Maximal Electroshock Seizure Test (17). Wistar rats weighing 160-240 g were subjected 
to electroshock-induced convulsions by passing an a.c. current of 150 mA for 0.2 sec between 
both eyeballs. This caused the immediate development of a full fledged convulsive syndrome 
consisting of a clonic phase followed by a hindlimb extension phase with an average duration 
of 12.9 _+ 1.2 sec. The time to reach the peak effect of the i.p.-administered analogue was 
determined at a dose of 80 mg/kg for ACPC and 50 mg/kg fdr the other three amino acids. 
Two groups of eight to ten rats each were tested by each compound. The animals were 
subjected to a convulsive current at 0.5, 2, 4, 6, and 8 hr after injection for one group and 
1, 3, 5 and 7 hr after injection for the second group. The time to achieve a peak effect and 
the duration of maximum anticonvulsant activity were then determined from the results of 
these experiments. 
Metrazol (Pentylenetetrazol) Seizure Test (17). Convulsions were elicited in male Swiss 
albino mice weighing 20-35 g by the subcutaneous injection of 85 mg/kg of metrazol. Dosages 
of amino acid analogue ranged from 40 mg/kg to 320 mg/kg for ACPC and from 100 mg/kg 
to 200 mg/kg for the other amino acids. 
RESULTS 
In the maximal electroshock seizure test of Swinyard (17), ACPC at 
a dose of 80 mg/kg afforded protection to 11 of 12 animals in the test group 
at 5 hr after injection. The other analogues were tested at a dose of 50 
mg/kg because of the much lower solubility of both 3-MACPC and 3- 
ACTHT. These compounds, however, afforded protection at 4 hr after 
injection rather than 5 hr as with ACPC. The results of these experiments 
(Tables II and III) show a dose-response relationship at 5 hr after injection 
for ACPC and at 4 hr for the other amino acids. The EDso for each amino 
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T A B L E  II 
TIME TO ACHIEVE MAXIMUM PROTECTION BY AMINO ACID ANALOGUE IN 
THE MAXIMAL ELECTROSHOCK TEST ~ 
80 mg/kg 50 mg/kg 50 mg/kg 50 mg/kg 
hr ACPC (%) MACPC (%) AIB (%) 3-ACTHT (%) 
0.5 1/8 15 2/8 25 0/8 0 0/8 0 
1.0 2/8 25 3/8 38 1/8 13 3/8 38 
2.0 5/8 62 3/8 38 4/8 50 4/8 50 
3,0 5/8 62 5/8 62 3/8 38 4/8 50 
4,0 6/8 75 7/8 88 4/8 50 4/8 50 
5.0 11/12 92 4/8 50 4/8 50 4/8 50 
6,0 4/8 50 3/8 38 3/8 38 4/8 50 
7,0 3/8 38 1/8 13 2/8 25 2/8 25 
a The number of animals protected in a group and the percentage protected at the indicated 
amino acid dose as a function of time. 
TABLE III 
DOSE-RESPONSE RELATIONSHIP OF AMINO ACID ANALOGUES a 
mg/kg ACPC % AIB % MACPC % 3-ACTHT % mg/kg 
20 2/10 20 3/11 27 6/14 43 5/13 38 25 
40 4/12 33 10/15 67 8/13 69 4/10 40 50 
80 7/12 58 7/8 88 10/12 83 5/8 63 100 
160 11/12 92 
a Dose-response relationship at 5 hr for ACPC and 4 hr for the other amino acids expressed 
as the number of animals in a group protected and the percentage of the group protected 
in the maximal electroshock test. 
acid was obtained by plotting the percentage of animals protected against 
the dose administered. For 3-MACPC the EDs0 was 35 mg/kg, for AIB 
the EDso was 40 mg/kg, for 3-ACTHT the EDs0 was 60 mg/kg, and for 
ACPC the EDs0 was 66 mg/kg. 
The effectiveness of these compounds against electroshock-induced 
convulsions was not carried over to metrazol-induced convulsions. None 
of the compounds afforded any protection to mice against metrazol-in- 
duced seizures. At best, only one animal in a given test group survived. 
Even at an extreme dose of 1280 mg/kg of ACPC no protection against 
metrazol-induced seizures was observed. The results of these experiments 
are summarized in Table IV. 
Although neural or other forms of toxicity were not specifically ex- 
plored, no alterations of stance and gait or of the place reflex were ob- 
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T A B L E  IV 
EFFECTIVENESS OF AMINO ACID ANALOGUES AGAINST METRAZOL-INDUCED 
CONVULSIONS IN MICE ~ 
mg/kg ACPC % mg/kg AIB % MACPC % 3-ACTHT % 
40 0/9 0 100 0/8 0 l/8 13 1/7 14 
80 0/10 0 200 0/8 0 0/8 0 0/2 0 
160 0/10 0 
320 1/5 20 
1280 1/6 19 
Metrazol test of analogue protection in Swiss Albino mice indicating the number of animals 
in the group that survived and the percent within the group that survived. 
served at doses of 200 mg/kg for AIB, 3-MACPC, 3-ACTHT, and 320 mg/ 
kg of ACPC in rats or mice. Such alterations in motor or reflex behavior 
would have been indicative of neurotoxicity (17); however, the absence 
of such alterations does not exclude neurotoxic effects which may require 
an extended time period and long-term administration of the compound 
before becoming evident. 
DISCUSSION 
The anticonvulsive activity of the four amino acid analogues as meas- 
ured by the maximal electroshock test clearly demonstrates that these 
compounds do provide a protective action. A ranking measure of their 
efficacy relative to other anticonvulsant agents can be made on the basis 
of their EDs0 values. On this scale all four compounds would be ranked 
as less effective than cannabidiol (18), phenobarbital (19), or diphenylhy- 
dantoin (19) but well above oxazolidinedione compounds such as trime- 
thadione or paramethadione (20). In contrast to the protective action of 
these amino acids in the maximal electroshock test, none of the com- 
pounds provided protection in mice, 4-5 hr after injection, against me- 
trazol. However,  Millichap (20) has pointed out that inactivity against 
metrazol is neither essential nor predictive of the efficacy of a compound 
in certain forms of epilepsy. 
The structural features of the amino acid analogues that were used for 
predictive purposes of anticonvulsant activity, namely the presence of a 
five-membered ring, a carbonyl group, and an amino function, have been 
shown to be valid criteria for such compounds. The activity of AIB can 
be rationalized within this scheme if the molecule is viewed as being a 
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fragment of a five-membered ring. The angle between the two methyl 
groups can reasonably be taken to be close to 109 ~ . All of the straight- 
and branched-chain amino acids have angles of this magnitude at the ~- 
carbon atom and its attached s p  3 hybridized bonds (21). The angle in 
ACPC and the other cyclic amino acids is 103-104 ~ (22,23). The bond 
lengths are essentially the same for all four compounds. 
The mechanism by which any anticonvulsant agent acts is still un- 
known. The various anticonvulsants that have been studied often share 
some properties in common but are quite different with respect to other 
properties. For most anticonvulsants even the site of action has not been 
determined. Nevertheless, one feature that must be common to all of 
these agents is that there exists a receptor site in the tissue, even if dif- 
ferent sites are needed for different compounds. These receptor sites must 
have certain conformational, geometric, and functional group require- 
ments in order to recognize and bind the anticonvulsive agent. For those 
compounds that possess five-membered rings, a carbonyl group and an 
amino function, e.g., hydantoins and oxazolidinediones, the recognition 
mechanism must be such that the compounds used in the present inves- 
tigation satisfy the requirements. In an aqueous milieu the primary binding 
mechanism is by hydrophobic interactions, and this feature is provided 
by the apolar hydrocarbon ring or the dimethyl groups of AIB. The at- 
tachment of apolar alkyl or aryl side chains to either the hydantoins, 
oxazolidinediones, succinimides, or the amino acid analogues would pro- 
vide the additional sites for hydrophobic interaction. That hydrophobic 
interactions play a dominant role in the interaction of amino acids and 
transport proteins has previously been demonstrated (3). There is no rea- 
son for the interaction mechanism to change in the present system. 
The results of this study also provide additional support for the hy- 
pothesis offive-membered ring geometry in certain classes of compounds 
as being associated with anticonvutsive activity. 
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